Patents by Inventor Stevan Graham Shaw

Stevan Graham Shaw has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Methods of Treatment Using Anti-IL-17A/F Antibodies
    Publication number: 20230287100
    Abstract: The invention relates to therapeutic uses of antibody molecules having specificity for antigenic determinants of both IL-17A and IL-17F in the treatment of dermatological and rheumatological diseases, such as psoriasis, psoriatic arthritis and axial spondyloarthritis.
    Type: Application
    Filed: October 11, 2022
    Publication date: September 14, 2023
    Inventors: Sophie Glatt, Lucian Ionescu, Margaret Jones, Ruth Oliver, Stevan Graham Shaw, Foteini Strimenopoulou, Venkata Pavan Kumar Vajjah
  • Methods of Treatment Using Anti-IL-17A/F Antibodies
    Publication number: 20230279093
    Abstract: The invention relates to therapeutic uses of antibody molecules having specificity for antigenic determinants of both IL-17A and IL-17F in the treatment of dermatological and rheumatological diseases, such as psoriasis, psoriatic arthritis and axial spondyloarthritis.
    Type: Application
    Filed: October 11, 2022
    Publication date: September 7, 2023
    Inventors: Sophie Glatt, Lucian Ionescu, Margaret Jones, Ruth Oliver, Stevan Graham Shaw, Foteini Strimenopoulou, Venkata Pavan Kumar Vajjah
  • Anti-FcRn Antibodies
    Publication number: 20230074381
    Abstract: The disclosure relates to antibodies specific to FcRn, formulations comprising the same, use of each in therapy, processes for expressing and optionally formulating said antibody, DNA encoding the antibodies and hosts comprising said DNA.
    Type: Application
    Filed: June 1, 2022
    Publication date: March 9, 2023
    Applicant: UCB Biopharma SRL
    Inventors: Helene Margaret Finney, Alastair David Griffiths Lawson, Stevan Graham Shaw, Bryan John Smith, Kerry Louise Tyson, Lara Kevorkian, Christoph Meier, Kaushik Sarkar, Paul Alan Atherfold
  • Methods of treatment using anti-IL-17A/F antibodies
    Patent number: 11492396
    Abstract: The invention relates to therapeutic uses of antibody molecules having specificity for antigenic determinants of both IL-17A and IL-17F in the treatment of dermatological and rheumatological diseases, such as psoriasis, psoriatic arthritis and axial spondyloarthritis.
    Type: Grant
    Filed: October 26, 2016
    Date of Patent: November 8, 2022
    Assignee: UCB BIOPHARMA SRL
    Inventors: Sophie Glatt, Lucian Ionescu, Margaret Jones, Ruth Oliver, Stevan Graham Shaw, Foteini Strimenopoulou, Venkata Pavan Kumar Vajjah
  • Anti-FcRn antibodies
    Patent number: 11384148
    Abstract: The disclosure relates to antibodies specific to FcRn, formulations comprising the same, use of each in therapy, processes for expressing and optionally formulating said antibody, DNA encoding the antibodies and hosts comprising said DNA.
    Type: Grant
    Filed: February 8, 2019
    Date of Patent: July 12, 2022
    Inventors: Helene Margaret Finney, Alastair David Griffiths Lawson, Stevan Graham Shaw, Bryan John Smith, Kerry Louise Tyson, Lara Kevorkian, Christoph Meier, Kaushik Sarkar, Paul Alan Atherfold
  • MULTI-SPECIFIC ANTIBODY MOLECULES HAVING SPECIFICITY FOR TNF-ALPHA, IL-17A and IL-17F
    Publication number: 20200277366
    Abstract: The invention relates to multi-specific antibody molecules having specificity for TNF alpha, IL-17A and IL-17F, therapeutic uses of the antibody molecules and methods for producing said antibody molecules.
    Type: Application
    Filed: December 14, 2016
    Publication date: September 3, 2020
    Applicant: UCB Biopharma SPRL
    Inventors: Ralph ADAMS, Pallavi BHATTA, Emma DAVE, Sam Philip HEYWOOD, David Taul HUMPHERYS, Diane MARSHALL, Stevan Graham SHAW, Daniel John LIGHTWOOD
  • Methods of Treatment Using Anti-IL-17A/F Antibodies
    Publication number: 20190292255
    Abstract: The invention relates to therapeutic uses of antibody molecules having specificity for antigenic determinants of both IL-17A and IL-17F in the treatment of dermatological and rheumatological diseases, such as psoriasis, psoriatic arthritis and axial spondyloarthritis.
    Type: Application
    Filed: October 26, 2016
    Publication date: September 26, 2019
    Inventors: Sophie Glatt, Lucian Ionescu, Margaret Jones, Ruth Oliver, Stevan Graham Shaw, Foteini Strimenopoulou, Venkata Pavan Kumar Vajjah
  • Anti-FcRn Antibodies
    Publication number: 20190248890
    Abstract: The disclosure relates to antibodies specific to FcRn, formulations comprising the same, use of each in therapy, processes for expressing and optionally formulating said antibody, DNA encoding the antibodies and hosts comprising said DNA.
    Type: Application
    Filed: February 8, 2019
    Publication date: August 15, 2019
    Applicant: UCB Biopharma SPRL
    Inventors: Helene Margaret Finney, Alastair David Griffiths Lawson, Stevan Graham Shaw, Bryan John Smith, Kerry Louise Tyson, Lara Kevorkian, Christoph Meier, Kaushik Sarkar, Paul Alan Atherfold
  • Anti-FcRn antibodies
    Patent number: 10233243
    Abstract: The disclosure relates to antibodies specific to FcRn, formulations comprising the same, use of each in therapy, processes for expressing and optionally formulating said antibody, DNA encoding the antibodies and hosts comprising said DNA.
    Type: Grant
    Filed: May 13, 2013
    Date of Patent: March 19, 2019
    Assignee: UCB Biopharma SPRL
    Inventors: Helene Margaret Finney, Alastair David Griffiths Lawson, Stevan Graham Shaw, Bryan John Smith, Kerry Louise Tyson, Lara Kevorkian, Christoph Meier, Kaushik Sarkar, Paul Alan Atherfold
  • Antibody molecules having specificity for human OX40
    Patent number: 10017575
    Abstract: The invention relates to antibody molecules having specificity for antigenic determinants of human OX40, therapeutic uses of the antibody molecules and methods for producing said antibody molecules.
    Type: Grant
    Filed: August 19, 2016
    Date of Patent: July 10, 2018
    Assignee: UCB Pharma S.A.
    Inventors: Alastair David Griffiths Lawson, Andrew Malcolm Nesbitt, Andrew George Popplewell, Stevan Graham Shaw, Diana Shpektor, Yi Zhang
  • Antibody molecules having specificity for human OX40
    Publication number: 20160355598
    Abstract: The invention relates to antibody molecules having specificity for antigenic determinants of human OX40, therapeutic uses of the antibody molecules and methods for producing said antibody molecules.
    Type: Application
    Filed: August 19, 2016
    Publication date: December 8, 2016
    Inventors: Alastair David Griffiths Lawson, Andrew Malcolm Nesbitt, Andrew George Popplewell, Stevan Graham Shaw, Diana Shpektor, Yi Zhang
  • Antibody molecules having specificity for human OX40
    Patent number: 9428570
    Abstract: The invention relates to antibody molecules having specificity for antigenic determinants of human OX40, therapeutic uses of the antibody molecules and methods for producing said antibody molecules.
    Type: Grant
    Filed: August 22, 2013
    Date of Patent: August 30, 2016
    Assignee: UCB Pharma S.A.
    Inventors: Alastair David Griffiths Lawson, Andrew Malcolm Nesbitt, Andrew George Popplewell, Stevan Graham Shaw, Diana Shpektor, Yi Zhang
  • Anti-FcRn Antibodies
    Publication number: 20150118240
    Abstract: The disclosure relates to antibodies specific to FcRn, formulations comprising the same, use of each in therapy, processes for expressing and optionally formulating said antibody, DNA encoding the antibodies and hosts comprising said DNA.
    Type: Application
    Filed: May 13, 2013
    Publication date: April 30, 2015
    Inventors: Helene Margaret Finney, Alastair David Griffiths Lawson, Stevan Graham Shaw, Bryan John Smith, Kerry Louise Tyson, Lara Kevorkian, Christoph Meier, Kaushik Sarkar, Paul Alan Atherfold
  • Antibody molecules having specificity for human OX40
    Patent number: 8614295
    Abstract: The invention relates to antibody molecules having specificity for antigenic determinants of human OX40, therapeutic uses of the antibody molecules and methods for producing said antibody molecules.
    Type: Grant
    Filed: February 17, 2010
    Date of Patent: December 24, 2013
    Assignee: UCB Pharma S.A.
    Inventors: Alastair David Griffiths Lawson, Andrew Malcolm Nesbitt, Andrew George Popplewell, Stevan Graham Shaw, Diana Shpektor, Yi Zhang
  • ANTIBODY MOLECULES HAVING SPECIFICITY FOR HUMAN OX40
    Publication number: 20130330344
    Abstract: The invention relates to antibody molecules having specificity for antigenic determinants of human OX40, therapeutic uses of the antibody molecules and methods for producing said antibody molecules.
    Type: Application
    Filed: August 22, 2013
    Publication date: December 12, 2013
    Applicant: UCB PHARMA S.A.
    Inventors: ALASTAIR DAVID GRIFFITHS LAWSON, ANDREW MALCOLM NESBITT, ANDREW GEORGE POPPLEWELL, STEVAN GRAHAM SHAW, DIANA SHPEKTOR, YI ZHANG
  • ANTIBODY MOLECULES HAVING SPECIFICITY FOR HUMAN OX40
    Publication number: 20100254978
    Abstract: The invention relates to antibody molecules having specificity for antigenic determinants of human OX40, therapeutic uses of the antibody molecules and methods for producing said antibody molecules.
    Type: Application
    Filed: February 17, 2010
    Publication date: October 7, 2010
    Inventors: Alastair David Griffiths Lawson, Andrew Malcolm Nesbitt, Andrew George Popplewell, Stevan Graham Shaw, Diana Shpektor, Yi Zhang